Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1986 March; 77(3): 887–893.
PMCID: PMC423475

Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").


A hereditary (three family members) deficiency of antithrombin III (AT-III) in which AT-III antigen (AT-III ag) is normal in spite of low heparin cofactor and antithrombin activity is described. Plasma levels were: AT-III ag, 0.92-0.96 U/ml; AT-III heparin cofactor activity, 0.54-0.62 U/ml; progressive antithrombin activity index, 0.13-0.18; anti-Xa activity, 0.50-0.56 U/ml. Plasma crossed immunoelectrophoresis (CIE) patterns performed with and without added heparin were normal, but serum CIE revealed a decreased complex peak. Purification of the patient's plasma AT-III by heparin-sepharose affinity chromatography showed a normal protein recovery and elution profile, but the purified AT-III fraction showed only 50% of the normal progressive thrombin neutralization and anti-Xa activity. When thrombin-antithrombin (TAT) complexes were formed by incubating with excess thrombin, SDS-polyacrylamide gel electrophoresis (PAGE) analysis revealed that half the patient AT-III formed TAT complexes while the remainder migrated as free AT-III. All the control AT-III formed TAT complexes. The patient's nonreacting AT-III (AT-III "Denver"), isolated by affinity chromatography, showed CIE and SDS-PAGE migration patterns characteristic of normal AT-III but failed to bind thrombin or Xa. Calculations from turnover studies in one patient and normal subjects with autologous 131I-AT-III suggested that AT-III "Denver" is removed from the plasma slightly more rapidly than normal. These studies indicate that the patients' variant AT-III molecule was characterized by normal heparin interaction but defective binding and inhibition of thrombin and Xa. These characteristics allow isolation of the nonreactive variant molecule by heparin-sepharose affinity chromatography.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed]
  • Sas G, Blaskó G, Bánhegyi D, Jákó J, Pálos LA. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia. Thromb Diath Haemorrh. 1974 Sep 30;32(1):105–115. [PubMed]
  • Ambruso DR, Jacobson LJ, Hathaway WE. Inherited antithrombin III deficiency and cerebral thrombosis in a child. Pediatrics. 1980 Jan;65(1):125–131. [PubMed]
  • Goodnight SH, Jr, Schaeffer JL, Sheth K. Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238. Comparison with immunoelectrophoretic and factor Xa inhibition assays. Am J Clin Pathol. 1980 May;73(5):639–647. [PubMed]
  • Von Kaulla E, Von Kaulla KN. Antithrombin 3 and diseases. Am J Clin Pathol. 1967 Jul;48(1):69–80. [PubMed]
  • Odegård OR, Lie M, Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis. 1976;5(5):265–275. [PubMed]
  • Andersson LO, Engman L, Henningsson E. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex. J Immunol Methods. 1977;14(3-4):271–281. [PubMed]
  • Damus PS, Rosenberg RD. Antithrombin-heparin cofactor. Methods Enzymol. 1976;45:653–669. [PubMed]
  • Reeve EB, Leonard B, Wentland SH, Damus P. Studies with 131I-labelled antithrombin III in dogs. Thromb Res. 1980 Nov 15;20(4):375–389. [PubMed]
  • Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed]
  • Ambruso DR, Leonard BD, Bies RD, Jacobson L, Hathaway WE, Reeve EB. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood. 1982 Jul;60(1):78–83. [PubMed]
  • Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood. 1983 Dec;62(6):1242–1250. [PubMed]
  • Sørensen PJ, Dyerberg J, Stoffersen E, Jensen MK. Familial functional antithrombin III deficiency. Scand J Haematol. 1980 Feb;24(2):105–109. [PubMed]
  • Sørensen PJ, Sas G, Petó I, Blaskó G, Kremmer T, Samu A. Distinction of two pathologic antithrombin III molecules: antithrombin III "Aalborg' and antithrombin III "Budapest'. Thromb Res. 1982 May 1;26(3):211–219. [PubMed]
  • Sas G, Pepper DS, Cash JD. Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest. Thromb Diath Haemorrh. 1975 Jun 30;33(3):564–572. [PubMed]
  • Girolami A, Marafioti F, Rubertelli M, Vicarioto MA, Cappellato G, Mazzuccato M. Antithrombin III Trento. A 'new' congenital AT III abnormality with a peculiar crossed-immunoelectrophoretic pattern in the absence of heparin. Acta Haematol. 1984;72(2):73–82. [PubMed]
  • Jørgensen M, Petersen LC, Thorsen S. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. J Lab Clin Med. 1984 Aug;104(2):245–256. [PubMed]
  • Carlström AS, Liedén K, Björk I. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. Thromb Res. 1977 Dec;11(6):785–797. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation